GLP-1 drugs for quitting smoking and managing weight after quitting: A review and combined analysis of clinical trials

GLP-1 receptor agonists may influence weight and metabolic outcomes related to smoking cessation.

• GLP-1 receptor agonists are known to reduce weight and improve metabolic health.
• Emerging evidence indicates a possible link between these agents and reward-related pathways.
• These pathways may provide benefits for individuals struggling with nicotine addiction.
• GLP-1 receptor agonists could help mitigate weight gain after quitting smoking.
• The study evaluates the effectiveness of GLP-1 receptor agonists specifically for smoking cessation.

Simplified